Evaluation of increased antibody titer COVID-19 after astrazeneca vaccination based on the age at UTA'45 Jakarta Vaccine Center

IF 0.2 Q4 PHARMACOLOGY & PHARMACY
Stefan Lukas, Diana Laila Ramatillah, Y. Aldi, F. Wahyuni, K. Khan
{"title":"Evaluation of increased antibody titer COVID-19 after astrazeneca vaccination based on the age at UTA'45 Jakarta Vaccine Center","authors":"Stefan Lukas, Diana Laila Ramatillah, Y. Aldi, F. Wahyuni, K. Khan","doi":"10.4103/ajprhc.ajprhc_4_23","DOIUrl":null,"url":null,"abstract":"Background: Vaccine is an essential tool to limit the health of the COVID-19 pandemic. AstraZeneca vaccine already provided promising effectiveness data. Still, the study must check the correlation between vaccination and antibody titer. Aim: This study aims to evaluate antibody titer after AstraZeneca vaccination based on the age group. Materials and Methods: This study used a prospective cross-sectional method with convenience sampling. Inclusion criteria were all Indonesian citizens above 18 years old who were vaccinated at UTA'45 Jakarta Vaccine Center with no history of COVID-19 before the vaccination and had filled up the informed consent. Results: This study's total sample was 102 females; 51.90%, residents of Java Island; 91.17% had comorbidities; 50,98%, smokers; 9,80%, alcohol drinker; 9,80%, exercise; 80,39%, blood pressure; 128/73, SpO2: 97,82. Most participants aged around 30 years had a body mass index of 23.33. Age, comorbidity, smoking, alcohol, and exercise habit significantly correlate with the increase of the participants' antibodies (P < 0.001). The age shows that the younger the participant, the higher the titer antibody 2 will be (P = 0.001, 95% confidence interval [CI], −1.935, −0.694). The exercise shows that the participant with the routine practice will have a higher titer antibody 2 (P = 0.002, 95% CI, 12.016, 51.791). Antibody titer for participants younger than 35 years old increased 5.7 times while for participants between 35 and 45 years old was 3.9 times. Another group (>45–55 years old) has shown an improvement in antibody titer at 1.7 times, but the last group (>55 years old) described an increase in antibody titer at 232.3 times. Conclusions: Age, comorbidity, smoking, alcohol, and exercise contributed to the increase in titer antibody 2 value of the AstraZeneca vaccine participants. Participants in the age group <35 years have an excellent immune system.","PeriodicalId":8534,"journal":{"name":"Asian Journal of Pharmaceutical Research and Health Care","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutical Research and Health Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ajprhc.ajprhc_4_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Vaccine is an essential tool to limit the health of the COVID-19 pandemic. AstraZeneca vaccine already provided promising effectiveness data. Still, the study must check the correlation between vaccination and antibody titer. Aim: This study aims to evaluate antibody titer after AstraZeneca vaccination based on the age group. Materials and Methods: This study used a prospective cross-sectional method with convenience sampling. Inclusion criteria were all Indonesian citizens above 18 years old who were vaccinated at UTA'45 Jakarta Vaccine Center with no history of COVID-19 before the vaccination and had filled up the informed consent. Results: This study's total sample was 102 females; 51.90%, residents of Java Island; 91.17% had comorbidities; 50,98%, smokers; 9,80%, alcohol drinker; 9,80%, exercise; 80,39%, blood pressure; 128/73, SpO2: 97,82. Most participants aged around 30 years had a body mass index of 23.33. Age, comorbidity, smoking, alcohol, and exercise habit significantly correlate with the increase of the participants' antibodies (P < 0.001). The age shows that the younger the participant, the higher the titer antibody 2 will be (P = 0.001, 95% confidence interval [CI], −1.935, −0.694). The exercise shows that the participant with the routine practice will have a higher titer antibody 2 (P = 0.002, 95% CI, 12.016, 51.791). Antibody titer for participants younger than 35 years old increased 5.7 times while for participants between 35 and 45 years old was 3.9 times. Another group (>45–55 years old) has shown an improvement in antibody titer at 1.7 times, but the last group (>55 years old) described an increase in antibody titer at 232.3 times. Conclusions: Age, comorbidity, smoking, alcohol, and exercise contributed to the increase in titer antibody 2 value of the AstraZeneca vaccine participants. Participants in the age group <35 years have an excellent immune system.
UTA'45雅加达疫苗中心基于年龄评估阿斯利康疫苗接种后COVID-19抗体滴度升高
背景:疫苗是限制COVID-19大流行健康的重要工具。阿斯利康疫苗已经提供了有希望的有效性数据。尽管如此,这项研究必须检查疫苗接种和抗体滴度之间的相关性。目的:本研究旨在评估阿斯利康疫苗接种后基于年龄组的抗体滴度。材料与方法:本研究采用前瞻性横断面法,便于抽样。纳入标准为所有在UTA'45雅加达疫苗中心接种疫苗、接种前无COVID-19病史并填写知情同意书的18岁以上印度尼西亚公民。结果:本研究共纳入102名女性;爪哇岛居民占51.90%;91.17%有合并症;50岁的98%,吸烟者;9、80%,饮酒者;9日,80%,运动;80,39%,血压;128/73, SpO2: 97,82。大多数30岁左右的参与者的身体质量指数为23.33。年龄、合并症、吸烟、饮酒和运动习惯与参与者抗体的增加显著相关(P < 0.001)。年龄显示,参与者越年轻,抗体2滴度越高(P = 0.001, 95%可信区间[CI], - 1.935, - 0.694)。结果显示,常规练习的参与者抗体2滴度较高(P = 0.002, 95% CI, 12.016, 51.791)。35岁以下参与者的抗体滴度增加了5.7倍,而35岁至45岁参与者的抗体滴度增加了3.9倍。另一组(45-55岁)的抗体滴度提高了1.7倍,但最后一组(55岁的>)的抗体滴度提高了232.3倍。结论:年龄、合并症、吸烟、饮酒和运动有助于阿斯利康疫苗参与者滴度抗体2值的升高。年龄<35岁的参与者具有良好的免疫系统。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信